Interpace Diagnostics Group, Inc. (IDXG) financial statements (2021 and earlier)

Company profile

Business Address MORRIS CORPORATE CENTER 1,
PARSIPPANY, NJ 07054
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments515132
Cash and cash equivalents515132
Receivables871010
Inventory, net of allowances, customer advances and progress billings2222
Inventory2222
Other current assets4454
Other undisclosed current assets(2)(2)(2)(2)
Total current assets:18262817
Noncurrent Assets
Operating lease, right-of-use asset553 
Property, plant and equipment7777
Intangible assets, net (including goodwill)21222324
Goodwill8888
Intangible assets, net (excluding goodwill)13141516
Other noncurrent assets0000
Other undisclosed noncurrent assets   4
Total noncurrent assets:33353335
TOTAL ASSETS:51616152
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5678
Accounts payable3345
Accrued liabilities0000
Employee-related liabilities1222
Taxes payable0000
Deferred revenue0000
Debt1112
Due to related parties  11
Disposal group, including discontinued operation1111
Business combination, contingent consideration, liability1111
Other undisclosed current liabilities8756
Total current liabilities:16161617
Noncurrent Liabilities
Long-term debt and lease obligation4413
Finance lease, liability0000
Operating lease, liability4413
Liabilities, other than long-term debt7775
Other liabilities4555
Business combination, contingent consideration, liability222 
Other undisclosed noncurrent liabilities(0)315
Total noncurrent liabilities:1014913
Total liabilities:26302530
Temporary equity, carrying amount   26
Stockholders' equity
Stockholders' equity attributable to parent(22)(16)(11)(4)
Common stock0000
Treasury stock, value(2)(2)(2)(2)
Additional paid in capital184183183183
Accumulated deficit(204)(198)(192)(186)
Other undisclosed stockholders' equity474747 
Total stockholders' equity:253036(4)
TOTAL LIABILITIES AND EQUITY:51616152

Income statement (P&L) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
Revenues8594
Cost of revenue(5)(4)(6)(5)
Gross profit:323(1)
Operating expenses(9)(7)(9)(10)
Operating loss:(6)(6)(6)(11)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)000
Interest and debt expense(0)(0)(0)(0)
Loss from continuing operations before income taxes:(6)(6)(6)(11)
Income tax expense (benefit)(0)(0)(0)0
Loss from continuing operations:(6)(6)(6)(11)
Loss from discontinued operations(0)(0)(0)(0)
Net loss attributable to parent:(6)(6)(6)(11)
Preferred stock dividends and other adjustments  3(0)
Other undisclosed net loss available to common stockholders, basic  (6) 
Net loss available to common stockholders, diluted:(6)(6)(10)(11)

Comprehensive Income ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
Net loss:(6)(6)(6)(11)
Comprehensive loss, net of tax, attributable to parent:(6)(6)(6)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: